KKR's Proposed Acquisition Of Assura Gets Merger Control Clearance From European Commission

KKR's acquisition of Assura plc for approximately £1.7 billion ($2.29 billion) has received merger control clearance from the European Commission, with only foreign direct investment clearance in Ireland remaining. The offer from Sana Bidco, owned by KKR and Stonepeak Partners, is 50.42 pence per share in cash plus retained dividends of 1.68 pence; Bidco has also entered into a £125 million loan agreement with Jefferies International to support the deal, which Assura shareholders will receive documentation for within 28 days. The acquisition, structured as a recommended takeover offer, remains subject to the satisfaction of the remaining regulatory condition.

Analysis

Kohlberg Kravis Roberts & Co. L.P. (KKR) is making significant progress in its acquisition of Assura plc, a specialist UK healthcare property investor, as evidenced by the European Commission's merger control clearance for the approximately £1.7 billion ($2.29 billion) transaction. This approval substantially mitigates deal uncertainty, with only the foreign direct investment clearance in Ireland remaining as a key regulatory hurdle. The offer from Sana Bidco, an entity jointly owned by funds advised by KKR and Stonepeak Partners, comprises 50.42 pence per share in cash along with the retention of dividends totaling 1.68 pence per Assura share. This offer structure has garnered a recommendation from Assura's board, particularly noteworthy given Assura's prior rejection of an offer from Primary Health Properties Plc. To facilitate the acquisition, Sana Bidco has secured a £125 million loan agreement with Jefferies International Limited. Assura's shares are trading at 50.13 pence, marginally below the cash component of the offer, reflecting the market's pricing of the residual regulatory risk and the time to deal completion. The impending publication of the Offer Document to Assura shareholders within 28 days will provide further details on the recommended takeover.

Key Decisions for Investors

• Assura shareholders should note the current share price of 50.13 pence offers a modest arbitrage opportunity relative to the 50.42 pence cash consideration plus 1.68 pence in retained dividends, with the final Irish FDI approval being the primary condition to monitor for deal consummation.
• For KKR investors, this transaction's progression represents positive execution in deploying capital into the defensive healthcare real estate sector, which is expected to yield stable, long-term income streams upon successful completion of the acquisition.
• Market participants should consider this deal's advancement as an indicator of sustained private equity interest in UK-based specialized real estate assets, potentially supporting valuations and further M&A activity within the sector, contingent on the final regulatory sign-off.